Research · PMID 39820213 · Landmark study

PubMed sourcedAbstract-based analysis

Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026

Clinician's guide to the management of azoospermia induced by exogenous testosterone or anabolic-androgenic steroids.

Asian journal of andrology · May 2025 · Manaf Al Hashimi, Germar-Michael Pinggera, Rupin Shah, Ashok Agarwal

What this study found

Azoospermia, defined as the absence of sperm in the ejaculate, is a well-documented consequence of exogenous testosterone (ET) and anabolic-androgenic steroid (AAS) use. These agents suppress the hypothalamic-pituitary-gonadal (HPG) axis, leading to reduced intratesticular testosterone levels and impaired spermatogenesis.

Landmark studyreview

Why this trial matters

TRT fertility and spermatogenesis review

How RAGMD uses this study

Clinical questions this paper informs

Synthesis lives on the evidence question — this page shows where the study sits in that analysis.

Primary study

Does testosterone therapy suppress fertility in men?

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reliably reduces spermatogenesis. Recovery after discontinuation is variable and may be incomplete in some men.

Open evidence analysis